Drugs / Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Cell therapy targets CD19, CD22 via depletion
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05225831 | Aug 2021 → Aug 2023 | B-cell acute lymphoblastic leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19/CD22 Chimeric Antigen Receptor T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05225831 ↗ |
| Action | Deplete | “The dual-CARs enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22.” NCT05225831 ↗ |
| Modality | Cell therapy | “A single infusion of CD19 and CD22 CAR-T cells.” NCT05225831 ↗ |
| Target | CD19 | “The dual-CARs enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22.” NCT05225831 ↗ |
| Target | CD22 | “The dual-CARs enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22.” NCT05225831 ↗ |